BioCryst Pharmaceuticals is projected to report Q3 2026 revenue of $165.68 million and earnings per share of $0.10, while the current stock price of $8.47 remains significantly below the average analyst target of $20.55.
Investors are primarily focused on the net revenue performance of ORLADEYO and the commercial adoption of the newly approved oral pellet formulation.
Following its first full year of profitability in 2025, BioCryst is working to sustain financial momentum while integrating its strategic acquisition of Astria Therapeutics. Analysts will also monitor clinical updates for the navenibart and BCX17725 pipelines as the company navigates an increasingly competitive hereditary angioedema market.